Recombinant EGFR (Matuzumab Biosimilar) anticorps
Aperçu rapide pour Recombinant EGFR (Matuzumab Biosimilar) anticorps (ABIN7795112)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Classe de qualité
-
-
Expression System
- Mammalian cells
-
Fonction
- Matuzumab Biosimilar, EGFR Monoclonal Antibody
-
Attributs du produit
- Matuzumab Biosimilar uses the same protein sequences as the therapeutic antibody matuzumab. Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity, competitively blocking natural ligand binding and blocking receptor-mediated downstream signalling, resulting in impaired tumor cell proliferation. Matuzumab (EMD-72000) is a humanized IgG1 MAb that not only binds with high specificity and affinity to EGFR, but also modulates antibody-dependent cellular cytotoxicity (ADCC).
-
Purification
- Protein A or G affinity column
-
Pureté
- >95 % by reducing SDS-PAGE
-
niveau d'endotoxine
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogène
- Human EGFR
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- EGFR (Matuzumab Biosimilar)
-
Autre désignation
- Matuzumab Biosimilar
-
Classe de substances
- Biosimilar
Antigène
-